On the 14th, AI drug development company Galax (CEO Seok Cha-ok) and Isu Abxis (CEO Yoo Jun-soo) signed an agreement for joint research on AI-based drug development. Through this agreement, the two companies will establish a collaborative biopharmaceutical R&D system by combining Isu Abxis' full-cycle drug development capabilities with Galaxy's AI drug design platform.
Galax possesses a proprietary platform, "GaluxDesign," that combines AI and physicochemical principles. It possesses the technology to de novo design sequences and structures optimized for specific disease-targeting proteins. Recently, the company announced the discovery of novel antibodies with high binding affinity for multiple therapeutic targets.
Isu Abxis has been strengthening its research and development capabilities based on its experience in developing antibody therapeutics.
Through this agreement, the two companies plan to combine AI design technology with actual development and production capabilities to increase the productivity and success rate of protein new drug development, and to discuss the role and application direction of AI throughout the entire new drug development process in the long term.
CEO Yoo Jun-soo said, “We will build a sophisticated and efficient research system by combining our long-term experience in new drug development with AI technology,” and CEO Seok Cha-ok said, “Through this agreement, we will verify the industrial value of AI protein design technology and create a new approach to new drug development.”
- See more related articles
You must be logged in to post a comment.